Non-Motor Symptoms of Parkinson Disease

PD is a progressive neurodegenerative disorder involving multiple neurotransmitter pathways in the brain and autonomic nervous system.
Associated clinical features include motor symptoms and various non-motor symptoms.

Motor Deficits: Current diagnosis relies on the assessment of motor deficits, which include:
- Bradykinesia: Abnormal slowness of movement.
- Rigidity: Stiffness and increased muscle tone.
- Tremor: Typically occurs unilaterally or asymmetrically.
Motor features stem largely from the loss of dopaminergic neurons in the substantia nigra pars compacta (SNc).
Symptomatic Therapy: Focused on dopamine replacement strategies (e.g., Levodopa).

As PD progresses and higher doses of levodopa are used:
- Wearing Off Periods: Re-emergence of motor symptoms (stiffness, slowness, tremor).
- Off Periods: Similar to "wearing off" but with more severe symptom severity.
- On Periods: Periods of effective dopamine replacement where motor function is restored.

Non-motor symptoms can manifest several years prior to motor symptoms and may include:
- Hyposmia: Reduced ability to detect odors.
- Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD): Disruption of normal sleep behaviors.
- Depression: Affective disturbances.
- Constipation: Gastrointestinal symptoms are common.
Non-motor symptoms often lead to significant morbidity and affect quality of life as disease progresses.

Cognitive impairment, particularly executive dysfunction and working memory issues, may arise during the early stages of PD, becoming more pronounced in individuals over 70 years of age.
- Global Cognitive Decline: Observed in later years as neurodegeneration progresses.
Cognitive impairments and other non-motor symptoms (e.g., autonomic dysfunction) may become the dominant clinical picture in later stages of PD.

Parkinson Disease exhibits multiple endophenotypes, some of which are characterized by non-motor symptoms.
Greater understanding of neuroanatomical and pharmacological bases of non-motor symptoms remain largely undefined, but insights are growing.
Research emphasizes the need for effective symptomatic interventions for non-motor features alongside dopamine-focused therapies.

Existing models, both toxin-based (like rotenone or 6-hydroxydopamine (6-OHDA)) and genetic (e.g., α-synuclein transgenic mice) have shown limited ability to replicate the non-motor features or the progressive nature of PD.
- Differences: Toxin models primarily affect dopaminergic mechanisms and lack the complexity of PD's pathogenesis.

Sensory Features: Sensory disturbances, especially pain, are prevalent. Pain characteristics include:
- Reported by a significant portion of patients (30 to 85%).
- Can be classified into nociceptive and neuropathic pain categories.
Olfactory Deficits: Hyposmia or anosmia occurs in more than 90% of PD cases, which may precede motor symptoms.
Visual Disturbances: Up to 78% of patients experience visual symptoms; some studies report 22% prevalence against age-matched controls.

Anxiety and Depression: Develop from premotor stages to late PD, frequently co-occurring. Anxiety affects 60% of patients.
- Non-motor fluctuations are more prominent during off periods of motor symptoms.
- Potential neurochemical bases differentiate anxiety from depression in PD.
Cognitive Deficits and Dementia: Affects up to 83% of individuals with PD. Cognitive decline often aligns with Lewy body density.
- Distinction from other dementias such as dementia with Lewy bodies or Alzheimer's can be challenging but critical for accurate diagnosis and management.
Fatigue and Apathy: Both affect a substantial number of individuals; apathy affects about 60%, and fatigue affects roughly 50%.

Sleep disturbances are common in PD, manifesting as:
- Daytime somnolence and sudden sleep attacks.
- Nocturnal sleep disturbances involving insomnia, sleep fragmentation, and RBD.
Dopaminergic treatments can either exacerbate or alleviate these symptoms depending on the context.
REM Sleep Behavior Disorder: Can occur early in disease progression and reflect underlying pathophysiology.

Autonomic dysfunction in PD may emerge before motor features and includes:
- Bladder dysfunction (e.g., nocturia, urgency), bowel dysfunction (constipation), and cardiovascular irregularities (e.g., orthostatic hypotension).
Gastrointestinal Dysfunction: Wide-ranging impacts on the digestive tract, with issues like reduced gastric emptying and excessive salivation noted as early symptoms.

The recognition of non-motor symptoms leading to early diagnosis presents a critical frontier in PD research.
Future research is needed to identify biomarkers associated with both motor and non-motor symptomatology.
Therapeutic strategies should target the entire spectrum of PD features rather than focusing solely on dopaminergic loss.

PD is a complex disorder comprising myriad symptoms, both motor and non-motor. Continued research will facilitate the development of comprehensive treatment strategies aimed at improving the quality of life for PD patients.